Phillip Frost's Significant Share Purchase Amid Downgrade: A Bull Case for OPKO Health?

Phillip Frost, CEO of OPKO Health, has purchased $737,747 worth of shares, increasing his holdings in the company. This insider activity coincides with Jefferies downgrading OPKO from Buy to Hold due to concerns about stagnant sales guidance for Ngenla, a growth hormone treatment developed with Pfizer. Frost's purchase does not change the immediate outlook for OPKO's biggest near-term catalyst, profitability improvements from asset sales and cost optimization.